1.Identification
1.1GHS Product identifier
1.2Other means of identification
1.3Recommended use of the chemical and restrictions on use
1.4Supplier's details
1.5Emergency phone number
2.Hazard identification
2.1Classification of the substance or mixture
Carcinogenicity, Category 2
Hazardous to the aquatic environment, short-term (Acute) - Category Acute 1
Hazardous to the aquatic environment, long-term (Chronic) - Category Chronic 1
2.2GHS label elements, including precautionary statements
2.3Other hazards which do not result in classification
none
3.Composition/information on ingredients
3.1Substances
4.First-aid measures
4.1Description of necessary first-aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
Fresh air, rest. Refer for medical attention.
In case of skin contact
Rinse and then wash skin with water and soap. Refer for medical attention .
In case of eye contact
First rinse with plenty of water for several minutes (remove contact lenses if easily possible), then refer for medical attention.
If swallowed
Rest. Refer for medical attention .
4.2Most important symptoms/effects, acute and delayed
SYMPTOMS: This compound is an irritant. ACUTE/CHRONIC HAZARDS: When heated to decomposition it emits toxic fumes of carbon monoxide, carbon dioxide, and NOx.
4.3Indication of immediate medical attention and special treatment needed, if necessary
Basic treatment: Establish a patent airway. Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with normal saline during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 ml/kg up to 200 ml of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poison A and B/
5.Fire-fighting measures
5.1Extinguishing media
Suitable extinguishing media
Fires involving this material can be controlled with a dry chemical, carbon dioxide or Halon extinguisher.
5.2Specific hazards arising from the chemical
Flash point data for this chemical are not available. It is probably combustible.
5.3Special protective actions for fire-fighters
Wear self-contained breathing apparatus for firefighting if necessary.
6.Accidental release measures
6.1Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust. For personal protection see section 8.
6.2Environmental precautions
Personal protection: particulate filter respirator adapted to the airborne concentration of the substance. Do NOT let this chemical enter the environment. Sweep spilled substance into covered sealable containers. Carefully collect remainder. Then store and dispose of according to local regulations.
6.3Methods and materials for containment and cleaning up
Pick up and arrange disposal. Sweep up and shovel. Keep in suitable, closed containers for disposal.
7.Handling and storage
7.1Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Avoid exposure - obtain special instructions before use.Provide appropriate exhaust ventilation at places where dust is formed. For precautions see section 2.2.
7.2Conditions for safe storage, including any incompatibilities
Well closed.
8.Exposure controls/personal protection
8.1Control parameters
Occupational Exposure limit values
no data available
Biological limit values
no data available
8.2Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of workday.
8.3Individual protection measures, such as personal protective equipment (PPE)
Eye/face protection
Safety glasses with side-shields conforming to EN166. Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Wear impervious clothing. The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace. Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique(without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands. The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and the standard EN 374 derived from it.
Respiratory protection
Wear dust mask when handling large quantities.
Thermal hazards
no data available
9.Physical and chemical properties
10.Stability and reactivity
10.1Reactivity
no data available
10.2Chemical stability
Stable under recommended storage conditions.
10.3Possibility of hazardous reactions
1,5-NAPHTHALENEDIAMINE neutralizes acids in exothermic reactions to form salts plus water. May be incompatible with isocyanates, halogenated organics, peroxides, phenols (acidic), epoxides, anhydrides, and acid halides. Flammable gaseous hydrogen may be generated in combination with strong reducing agents, such as hydrides.
10.4Conditions to avoid
no data available
10.5Incompatible materials
no data available
10.6Hazardous decomposition products
When heated to decomposition it emits toxic fumes of /nitrogen oxide/.
11.Toxicological information
Acute toxicity
Skin corrosion/irritation
no data available
Serious eye damage/irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
No data are available in humans. Limited evidence of carcinogenicity in animals. OVERALL EVALUATION: Group 3: The agent is not classifiable as to its carcinogenicity to humans.
Reproductive toxicity
no data available
STOT-single exposure
no data available
STOT-repeated exposure
no data available
Aspiration hazard
no data available
12.Ecological information
12.1Toxicity
12.2Persistence and degradability
1,5-Naphthalenediamine, present at 100 mg/l, reached 0% of its theoretical BOD in 4 weeks using an activated sludge inoculum at 30 mg/l and the Japanese MITI test(1). No biodegradation data was located for 1,5-naphthalenediamine in soil or water(SRC).
12.3Bioaccumulative potential
A BCF of 1.5 was measured for carp exposed to 0.02 mg/l of 1,5-naphthalenediamine for 6 weeks(1). According to a classification scheme(2), this BCF value suggests that bioconcentration in aquatic organisms is low(SRC).
12.4Mobility in soil
Using a structure estimation method based on molecular connectivity indices(1), the Koc for 1,5-naphthalenediamine can be estimated to be 5,000(SRC). According to a classification scheme(2), this estimated Koc value suggests that 1,5-naphthalenediamine is expected to have slight mobility in soil. The pKa of 1,5-naphthalenediamine is 4.44(3), indicating that this compound will partially exist in the protonated form in the environment under acidic conditions and cations generally adsorb to organic carbon and clay more strongly than their neutral counterparts(4). Primary and secondary aromatic amines are also susceptible to strong irreversible binding to humic material due to the high reactivity of the aromatic amino group(5).
12.5Other adverse effects
no data available
13.Disposal considerations
13.1Disposal methods
Product
The material can be disposed of by removal to a licensed chemical destruction plant or by controlled incineration with flue gas scrubbing. Do not contaminate water, foodstuffs, feed or seed by storage or disposal. Do not discharge to sewer systems.
Contaminated packaging
Containers can be triply rinsed (or equivalent) and offered for recycling or reconditioning. Alternatively, the packaging can be punctured to make it unusable for other purposes and then be disposed of in a sanitary landfill. Controlled incineration with flue gas scrubbing is possible for combustible packaging materials.
14.Transport information
14.1UN Number
14.2UN Proper Shipping Name
14.3Transport hazard class(es)
14.4Packing group, if applicable
14.5Environmental hazards
14.6Special precautions for user
no data available
14.7Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
no data available
Deutsche
Español
français
italiano
português
日本語
한국어
العربية
русский
bahasa Indonesia
Tiếng Việt

Folic acid,59-30-3
MK-4827 (HCl)
Folic acid
5-Bromo-2-chloropyrimidine 32779-36-5
Niraparib
(R)-tert-butyl 3-(4-aMinophenyl)piperidine-1-carboxylate
tert-butyl 3-(4-aminophenyl)piperidine-1-carboxylate
(3S)-3-[4-[7-[[(1,1-Dimethylethyl)amino]carbonyl]-2H-indazol-2-yl]phenyl]-1-piperidinecarboxylic acid 1,1-dimethylethyl ester
(3S)-3-(4-Bromophenyl)-1-piperidinecarboxylic acid 1,1-dimethylethyl ester
3-(4-Bromophenyl)piperidine-1-carboxylic acid tert-butyl ester
3-Chloro-4-(3-fluorobenzyloxy)nitrobenzene
Niraparib p-toluenesulfonate
N-(1,1-Dimethylethyl)-2-[4-(3S)-3-piperidinylphenyl]-2H-indazole-7-carboxamide
2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide
Alectinib
Benzaldehyde,4-(2-methylpropoxy)
2-(4-ethyl-3-iodophenyl)-2-Methylpropanoic acid
6-cyano-2-(2-(4-ethyl-3-(4-morpholinopiperidin-1-yl)phenyl)propan-2-yl)-1H-indole-3-carboxylic acid
9-ethyl-8-iodo-6,6-diMethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile
6-broMo-7-Methoxy-1,1-diMethyl-3,4-dihydronaphthalen-2(1H)-one
tert-butyl 4-(4-ethyl-3-iodophenyl)-4-methyl-3-oxopentanoate
9-broMo-8-hydroxy-6,6-diMethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile
9-ethyl-6,6-diMethyl-8-(4-Morpholinopiperidin-1-yl)-11-oxo-5a,6,11,11a-tetrahydro-5H-benzo[b]carbazole-3-carbonitrile hydrochloride
tert-butyl 6-cyano-2-(2-(4-ethyl-3-iodophenyl)propan-2-yl)-1H-indole-3-carboxylate
ethyl 2-(4-broMophenyl)-2-Methylpropanoate
ert-Butyl (4R-cis)-6-formaldehydel-2,2-dimethyl-1,3-dioxane-4-acetate
(2S)-Hydroxy(phenyl)acetic acid (2R)-N-benzyl-1-(4-methoxyphenyl)propan-2-amine
5-Tosyladenosine
Filgotinib
3-amino-2-chloroacrolein
2-Methylpyrazolo[1,5-a]pyrimidine-6-carboxamide
11-(1-Methylpiperidin-4-ylidene)-6,11-dihydro-5H-benzo[d]iMidazo[1,2-a]azepine
1-(4-(1-PHENETHYL-1H-IMIDAZOLE-2-CARBONYL)PIPERIDIN-1-YL)ETHANONE
ethyl (3R)-5-amino-3-hydroxypentanoate,hydrochloride
LAS191954 free base
tert-butyl 5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-ylcarbamate
ABT-494 Intermeidate N-2
abt594 Intermediate
LOXO101 Intermediate 2
LOXO101 Intermediate 1
Deutetrabenazine intermediate N-2
Deutetrabenazine intermediate N-1
Naldemedine tosylate intermediate
Naldemedine tosylate intermediate N-2
Naldemedine
Eribulin
2-BroMo-1-quinolin-6-yl-ethanone
6-[(6-Bromo-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)methyl]-7-fluoroquinoline
tert-butyl (S)-2-((tert-butoxycarbonyl)amino)-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanoate
7-Trifluoromethyl-imidazo[1,2-a]pyridine
methyl 4-(aminomethyl)-3-chlorobenzoate
methyl 3-oxo-2-(trifluoromethyl)butanoate
2-AMino-4,5,6,7-tetrahydro-benzo[b]thiophene-3-carboxylic acid tert-butyl ester
Methanone, (2-aMino-5-Methoxyphenyl)(4-chlorophenyl)
benzyl 5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylate
3-(1H-pyrazol-5-yl)phenol
4-(1H-Pyrazol-3-yl)aniline
1-(5-bromo-pyridin-2-yl)-2,2-dimethyl-propan-1-ol
1-(5-bromo-pyridin-2-yl)-2-methyl-propan-1-ol
Benzenemethanol, a-[(1S)-1-aminoethyl]-4-hydroxy-,(aR)
2-{[3-(4-Fluorophenyl)-4-oxo-3,4,6,7-tetrahydrothieno[3,2-d]pyrim idin-2-yl]sulfanyl}-N-(6-methyl-1,3-benzothiazol-2-yl)acetamide
2-((3-(2-methoxyphenyl)-4-oxo-3,4,6,7-tetrahydrothieno[3,2-d]pyrimidin-2-yl)thio)-N-(6-methylbenzo[d]thiazol-2-yl)acetamide
N-(6-Methyl-2-benzothiazolyl)-2-[(3,4,6,7-tetrahydro-4-oxo-3-phenylthieno[3,2-d]pyrimidin-2-yl)thio]-acetamide
(R)-(-)-1-(4-methoxyphenyl)-2-benzylaminopropane
4(3H)-Quinazolinone,7-bromo-6-chloro-3-[3-(3-hydroxy-2-piperidinyl)-2-oxopropyl]
9-OXO-1,2,3,9-TETRAHYDRO-PYRROLO[2,1-B]QUINAZOLINE-6-CARBOXYLIC ACID
2-(2-TRIFLUOROMETHYL-PHENYL)-PYRROLIDINE
(-)-4(R)-(2-Chloro-4-fluorophenyl)-2-(3,5-difluoropyridin-2-yl)-6-methyl-1,4-dihydropyrimidine-5-carboxylic acid methyl ester
2-Butenoic acid, 2-hydroxy-4-[5-(1-Methylethyl)-2,4-bis(phenylMethoxy)phenyl]-4-oxo-, ethyl ester
ALK inhibitor 2
Cefmenoxime hydrochloride
(S)-N-1-Boc-N-4-Cbz-2-piperazinecarboxylic acid
Avermectin
L-CANAVANINE SULFATE
3-Fluoropropiophenone 455-67-4
3-Hydroxypropiophenone 13103-80-5
2-Cyano-5-chloropyrimidine 38275-56-8
N-Formylpiperidine 2591-86-8
Indazole-3-carboxylic acid 4498-67-3
5-Bromo-2-cyanopyrimidine 38275-57-9
4,4-Dibromobenzophenone 3988-03-2
1,2,3,4-Tetrahydro-benzo[b]azepin-5-one 1127-74-8
4038-14-6,(3,4-dimethoxyphenyl)-phenylmethanone 4038-14-6
2-Amino-5-bromopyrimidine 7752-82-1
Triphenylbismuth 603-33-8
3-Ethynylimidazo[1,2-a]pyridine 943320-53-4
4-Nitrophenylacetonitrile 555-21-5
2-(4-aminophenyl)acetonitrile 3544-25-0
isoxazole 288-14-2
5-Methylisoxazole 5765-44-6
3-Aminoisoxazole 1750-42-1
2-Hydroxydiphenylmethane 28994-41-4
2,5-Difluorobenzyl Cyanide 69584-87-8
2,4-Difluorophenylacetonitrile 656-35-9
2,5-Difluorophenylacetic acid 85068-27-5
2,4-Difluorophenylacetic acid 81228-09-3
3-trifluoromethylbenzoic acid 454-92-2
2-[3-(trifluoromethyl)phenyl]acetonitrile 2338-76-3
2-[3-(trifluoromethyl)phenyl]acetic acid 351-35-9
3-Chlorobenzoyl chloride 618-46-2
3-Chlorobenzaldehyde 587-04-2
3-chlorobenzoic acid 535-80-8
3-Chlorobenzyl chloride 620-20-2
3-Chlorobenzyl cyanide 1529-41-5
2-(3-chlorophenyl)acetic acid 1878-65-5
Dimethylchloroacetal 97-97-2
Chloroacetaldehyde diethyl acetal 621-62-5
2-bromo-1,1-diethoxyethane 2032-35-1
2,2-dimethoxyethanamine 22483-09-6
2,2-Diethoxyethylamine 645-36-3
2-Methylphenylacetic acid 644-36-0
3-Isochromanone 4385-35-7
2,5-Dimethylphenylacetic acid 13612-34-5
2,4-Dimethylphenylacetic Acid 6331-04-0
2,5-Dimethylphenylacetonitrile 16213-85-7
2,4-Dimethylphenylacetonitrile 68429-53-8
5-CHLORO-2-FLUOROBENZOYL CHLORIDE 394-29-6
5-Chloro-2-fluorobenzoic acid 394-30-9
2,5-Dichlorobenzaldehyde 6361-23-5
2,5-Dichlorobenzoic acid 50-79-3
2,5-DICHLOROBENZOYL CHLORIDE 2905-61-5
2,2-Azobis(2-methylpropionamidine) dihydrochloride 2997-92-4
L-Phenylalanine, 1-methylethyl ester, hydrochloride 95585-78-7
Diphenylphosphoryl azide 26386-88-9
Methyl 4-(bromomethyl)benzoate 2417-72-3
Tideglusib 865854-05-3
Disodium 7,7-(carbonyldiimino)bis(4-hydroxynaphthalene-2-sulphonate) 20324-87-2
SU 6656 330161-87-0
Saccharin 1-methylimidazole 482333-74-4
CeMMEC13 1790895-25-8
Rabusertib 911222-45-2
Salermide 1105698-15-4
EST 88321-09-9
SC79 305834-79-1
C646 328968-36-1
1-(2-bromophenyl)-3-(2-hydroxy-4-nitrophenyl)urea 182498-32-4
Dp44mT 152095-12-0
Deguelin 522-17-8
PD168393 194423-15-9
YO01027 209984-56-5
DC10539 1822358-25-7
8-OH-DPAT 78950-78-4
YU238259 1943733-16-1
Scriptaid 287383-59-9
Velpatasvir 1377049-84-7
OTX015 202590-98-5
(+)-JQ-1 1268524-70-4
(-)-JQ-1 1268524-71-5
LY 900009 209984-68-9
LY-411575 209984-57-6
(4-nitrophenyl) 4-[bis(1,3-benzodioxol-5-yl)-hydroxymethyl]piperidine-1-carboxylate 1101854-58-3
N,N-dimethyl-2-oxo-1,3-dihydroindole-5-sulfonamide 170565-89-6
5,6,11,12-tetrahydrodibenzo[1,2-b:1,2-g][8]annulene 1460-59-9
Tetraphenylmethane 630-76-2
2-chloro-6-[(2R)-2-hydroxy-3-[(2-methyl-1-naphthalen-2-ylpropan-2-yl)amino]propoxy]benzonitrile 284035-33-2
N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-methyl-1-oxo-1,2-dihydroisoquinoline-4-carboxamide 440662-09-9
N-[2-[2-(4-chlorophenyl)-1,3-thiazol-4-yl]ethyl]butanamide 932986-18-0
5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile 1234015-52-1
3-Methyl-3-[(1E)-2-phenylethenyl]-3,2:5,2:5,3-quaterpyridine 1651890-44-6
3-[4-(Dimethylamino)-3-biphenylyl]-1,1-dimethylure 1469924-27-3
8-Methoxy-N,N-dipropyl-1,2,3,4-tetrahydro-2-naphthalenamine 3897-94-7
4-{4-[(4-{[3-(Acryloylamino)phenyl]amino}-5-fluoro-2-pyrimidinyl) amino]phenoxy}-N-methyl-2-pyridinecarboxamide 1202759-32-7
1,4-Dihydro-2,6-dimethyl-3-nitro-4-(2-trifluoromethylphenyl)-pyridine-5-carboxylic acid methyl ester 71145-03-4
2-[[3-[[2-(dimethylamino)phenyl]methyl]-2-pyridin-4-yl-1,3-diazinan-1-yl]methyl]-N,N-dimethylaniline 500579-04-4
CC-122 1015474-32-4
Bioymifi 1420071-30-2
N-(4-chlorophenyl)-1-(3-(furan-2-yl)benzoyl)piperidine-3-carboxamide 1443437-74-8
E-64C 76684-89-4
2-iodo-6-methoxybiphenyl 84253-78-1
pomalidomide 19171-19-8
Stearoylbenzoylmethane 58446-52-9
benzocaine 94-09-7
tranexamic acid 1197-18-8
lidocaine 137-58-6
lidocaine hydrochloride 73-78-9
Tetracaine hydrochloride 136-47-0
4-(1-phenylethyl)benzene-1,3-diol 85-27-8
Resazurin sodium salt 62758-13-8
4704-94-3 2-(HYDROXYMETHYL)-1,3-PROPANEDIOL
L-Tyrosine 60-18-4
L-Histidine 71-00-1
3,5-Bis(bromomethyl)toluene 19294-04-3
Bis(4-methylphenyl)methanol 885-77-8
5-Fluoroorotic Acid Hydrate 207291-81-4
1,3,5-Trimethyl-1H-pyrazole-4-carboxylic acid 1125-29-7
5-Amino-2-chloro-4-fluorophenol 84478-72-8
Gabapentin-lactam 64744-50-9
EP-Directory listing
2-(5-Methyl-2-phenyl-1,3-oxazol-4-yl)ethan-1-ol 103788-65-4
2-Amino-6-cyclopropylamino-9H-purine 120503-69-7
Chromic chloride hexahydrate 10060-12-5
EP-Directory listing 3

